Related Experiment Videos
Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease
1Mount Sinai Medical Center-Miami Heart Institute and Department of Medicine, Epidemiology, and Public Health, University of Miami School of Medicine, Miami Beach, Florida 33140, USA. PROFCHHMD@prodigy.net
Insights
Managing global cardiovascular disease (CVD) risk, particularly elevated lipid levels, is crucial. Statins effectively reduce CVD events, yet many at-risk patients remain undertreated or not at treatment goals.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) poses a significant health burden.
- Management of individual risk factors is important, but global risk assessment is optimal.
- Elevated lipid levels are a major contributor to overall CVD risk.
Purpose of the Study:
- To emphasize the importance of managing global CVD risk.
- To highlight the role of lipid reduction in mitigating CVD.
- To discuss the benefits and current underutilization of statins.
Main Methods:
- Review of clinical guidelines and evidence regarding CVD risk management.
- Focus on the role of lipid-lowering therapies, specifically statins.
- Analysis of patient treatment status relative to established goals.
Main Results:
- Elevated lipid values significantly contribute to global CVD risk.
- Statins (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) demonstrate clear clinical benefits in reducing myocardial infarction, stroke, and mortality.
- A significant gap exists between the known benefits of statins and their actual use, with many at-risk patients undertreated or not achieving lipid goals.
Conclusions:
- Comprehensive management of global CVD risk is essential for effective patient care.
- Lipid reduction, particularly through statin therapy, is a cornerstone of CVD prevention.
- Addressing the undertreatment and suboptimal goal attainment of statin therapy is critical to improve patient outcomes and reduce the incidence of cardiovascular events.
Abstract:
Although guidelines for individual risk factors for cardiovascular disease (CVD) assist the healthcare provider, management of the global risk profile of patients is the optimal means to minimize risk. Regardless of whether patients have one or more risk factors, elevated lipid values are generally considered to be a major contributor to global CVD risk. Therefore, reduction of lipid levels is one of the most effective methods to reduce risk of CVD. The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor class of drugs (also known as statins) has documented clinical benefits for reducing the incidence of myocardial infarction, stroke, death from CVD, and total death. Despite widespread acknowledgment of the very favorable benefit-to-risk ratio of the statins, most at-risk patients either are not being treated or are not at the goals defined by the National Cholesterol Education Program.